AGA living guideline for moderate-to-severe Crohn's disease (16 recommendations): advanced therapies such as infliximab, adalimumab and risankizumab over no treatment; initial advanced therapy over step therapy; against thiopurine monotherapy for induction.
Guideline
Scott et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease